A randomized clinical trial for evaluating effects of activated donor liver mononuclear cells inoculation on liver transplantation recipients with hepatitis C (HCV).

INTERVENTION: Participated patients will be randomly divided into two groups. One is cell therapy group and the other is untreated group. Patients in cell therapy group are injected activated donor liver mononuclear cells 3 days after liver transplantation. Patients in untreated group are injected placebo without cells. CONDITION: Liver transplantation recipients with HCV PRIMARY OUTCOME: 5‐year survival rate, and SVR SECONDARY OUTCOME: Adverse events, Postoperative infectious complication rate, Median overall survival INCLUSION CRITERIA: Patients who are expected to be recipients for living‐donor liver transplantation Patients who have submitted a written informed consent Patients with hepatitis C